Navigation Links
Senetek PLC Reports 2007 Financial Results
Date:4/15/2008

Investor Conference Call Scheduled for April 24

NAPA, Calif., April 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced results for the fourth quarter and year ended December 31, 2007.

Revenue for the year ended December 31, 2007 were $26,471,000, compared with $8,431,000 reported in 2006. Revenues for the fourth quarter of 2007 were $223,000, compared with $2,130,000 for the same period in the prior year.

Net income for the year ended December 31, 2007 totaled $18,632,000 or $2.41 per diluted share compared to $1,883,000 or $0.24 per diluted share in 2006. Net loss for the fourth quarter of 2007 was $1,706,000, or $0.22 per diluted share compared with net income of $575,000, or $0.08 per diluted share in the fourth quarter of 2006.

Cash flow from operations for the year ended December 31, 2007 increased to $18,019,000 compared with $1,290,000 in 2006.

The increase in 2007 revenues, net income and cash flow compared to 2006 is primarily attributable to the effect of the previously announced grant of a paid up license for Kinetin and Zeatin to Valeant Pharmaceuticals Inc. in March 2007 which contributed $24,750,000 to skincare revenues in the first quarter of 2007.

The decrease in 2007 fourth quarter revenues and net income compared to fourth quarter 2006 is primarily attributable to the elimination of Kinetin and Zeatin royalties after March 2007.

"We look forward to updating our shareholders on April 24th regarding our plans for the remainder of 2008," said Frank J. Massino, Senetek's Chairman and CEO.

The Company will conduct its quarterly teleconference call for investors on Thursday, April 24, 2008 at 9:00 a.m. Pacific, 12:00 p.m. Eastern to be hosted by Mr. Frank J. Massino, Chairman & CEO and Mr. William F. O'Kelly, Chief Financial Officer. The domestic dial-in number is 877-593-8638; the international dial-in number is 706-634-9240, conference ID: 43869518. Replay of the conference call will be available until April 30, 2008. Domestic Replay dial-in 800-642-1687, International Replay dial-in 706-645-9291, replay conference ID: 43869518.

About Senetek PLC:

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.

For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward- looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts
2. Senetek PLC Announces Launch of New Website
3. Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
4. Senetek PLC Reports Third Quarter 2007 Financial Results
5. Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment
6. Exponent Reports First Quarter 2008 Results
7. J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience
8. Marijuana use on the rise among Ontario adults, CAMH reports
9. Longs Reports Preliminary March Retail Drug Store Sales
10. CardioDynamics Reports 22% Revenue Growth in First Quarter 2008
11. IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: